Capstan Therapeutics presents preclinical data on lead in vivo CAR-T candidate, CPTX2309, with plans to advance into the ...

Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

WASHINGTON -- Rheumatoid arthritis (RA) patients who achieved sustained remission had better long-term outcomes than those with lingering low-level symptoms, a single-center study found -- casting ...

Older patients with a higher comorbidity burden who have nongonococcal bacterial knee septic arthritis are at greater risk ...

Substantial improvements in ultrasound technology and expanded use of it have necessitated an update of the 2012 ...

There are multiple chapters near you. Select your preferred chapter.

Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence ...

SetPoint Medical, a clinical-stage healthcare company dedicated to people living with chronic autoimmune diseases, today ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory B-cell lymphoma at the American College of Rheumatology ...

Fate Therapeutics (FATE) stock rallied 37% Monday on positive Phase 1 study data for its cell therapies FT819 and FT522. Read ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the first patient treated in its FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus – ...